S
Sung Kim
Researcher at Samsung Medical Center
Publications - 397
Citations - 10049
Sung Kim is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 43, co-authored 320 publications receiving 8033 citations. Previous affiliations of Sung Kim include Chungbuk National University & Electronics and Telecommunications Research Institute.
Papers
More filters
Journal ArticleDOI
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu,Jeeyun Lee,Michael Nebozhyn,Kyoung-Mee Kim,Jason C. Ting,Swee Seong Wong,Jiangang Liu,Yong Gang Yue,Jian Wang,Kun Yu,Xiang S. Ye,In-Gu Do,Shawn Liu,Lara Gong,Jake Fu,Jason Gang Jin,Min Gew Choi,Tae Sung Sohn,Joon-Ho Lee,Jae Moon Bae,Seung Tae Kim,Se Hoon Park,Insuk Sohn,Sin-Ho Jung,Patrick Tan,Ronghua Chen,James S. Hardwick,Won Ki Kang,Mark Ayers,Dai Hongyue,Christoph Reinhard,Andrey Loboda,Sung Kim,Amit Aggarwal +33 more
TL;DR: This work uses gene expression data to describe four molecular subtypes linked to distinct patterns of molecular alterations, disease progression and prognosis in gastric cancer, and describes key molecular alterations in each of the four subtypes using targeted sequencing and genome-wide copy number microarrays.
Journal ArticleDOI
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee,Do Hoon Lim,Sung Kim,Se Hoon Park,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Min Gew Choi,Tae Sung Sohn,Jae Hyung Noh,Jae Moon Bae,Yong Chan Ahn,Insuk Sohn,Sin-Ho Jung,Sin-Ho Jung,Cheol Keun Park,Kyoung-Mee Kim,Won Ki Kang +17 more
TL;DR: The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in Gastric cancer and a subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.
Journal ArticleDOI
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses
Se Hoon Park,Tae Sung Sohn,Jeeyun Lee,Do Hoon Lim,Min Eui Hong,Kyoung-Mee Kim,Insuk Sohn,Sin-Ho Jung,Min Gew Choi,Jun Ho Lee,Jae Moon Bae,Sung Kim,Seung Tae Kim,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Won Ki Kang +16 more
TL;DR: In D2-resected GC, both adjuvant chemotherapy and chemoradiotherapy are tolerated and equally beneficial in preventing relapse.
Journal ArticleDOI
Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project
Bo Hwa Sohn,Jun Eul Hwang,Hee Jin Jang,Hee Jin Jang,Hyun-Sung Lee,Sang Cheul Oh,Jae-Jun Shim,Keun Wook Lee,Eui Hyun Kim,Sun Young Yim,Sangho Lee,Jae Ho Cheong,Woojin Jeong,Jae Yong Cho,Joo Hee Kim,Jungsoo Chae,Jeeyun Lee,Won Ki Kang,Sung Kim,Sung Hoon Noh,Jaffer A. Ajani,Ju Seog Lee +21 more
TL;DR: The prediction model successfully stratified patients by survival and adjuvant chemotherapy outcomes, and EBV subtype was associated with the best prognosis, and GS sub type wasassociated with the worst prognosis.
Journal ArticleDOI
Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis.
M. Constanza Camargo,Woo Ho Kim,Anna Maria Chiaravalli,Kyoung-Mee Kim,Alejandro H. Corvalan,Keitaro Matsuo,Jun Yu,Joseph J.Y. Sung,Roberto Herrera-Goepfert,Fernando Meneses-Gonzalez,Yuko Kijima,Shoji Natsugoe,Linda M. Liao,Jolanta Lissowska,Sung Kim,Nan Hu,Carlos González,Y. Yatabe,Chihaya Koriyama,Stephen M. Hewitt,Suminori Akiba,Margaret L. Gulley,Philip R. Taylor,Charles S. Rabkin +23 more
TL;DR: It is suggested that tumour EBV positivity is an additional prognostic indicator in gastric cancer, and the mechanisms underlying this protective association are warranted.